Result(s)* 40 of 98 centres replied to the survey. 78% consented to become involved in an international registry. 63% of centres who replied receive between 50 - >100 referrals of ovarian cancer per year and 90% perform HIPEC in ovarian cancer. 79% (31/40) stated they had been practising CRS & HIPEC for >10 years. The number of CRS with HIPEC per year performed was <20 cases in 56% of respondents and >50 in 4%.

21% of centres held international accreditation for ovarian cancer CRS and 51% held national accreditation. Of interest was that 82% reported that no certification was required for the administration of HIPEC in their country.

Conclusion* Given the multiple reports demonstrating variations in practice across the globe we believe this could be a very important opportunity for implementing change for women with ovarian cancer. For centres that consented to participation a further survey will be issued focusing on operating standards for CRS in ovarian cancer and protocols for HIPEC administration.

1054

BLOOD-BASED DETECTION OF CIRCULATING DICKKOPF-1 AS A PROGNOSTIC BIOMARKER IN OVARIAN CANCER PATIENTS

^{1,2}P Wimberger*, ^{1,2}DM Klotz, ^{1,2}T Link, ^{1,2}M Goeckenjan, ³N Jaschke, ³LC Hofbauer, ³A Göbel, ³TD Rachner, ^{1,2}JD Kuhlmann. ¹Technische Universität Dresden, Department of Gynecology and Obstetrics, Dresden, Germany; ²National Center for Tumor Diseases, Partner site Dresden (NCT), Dresden, Germany; ³Technische Universität Dresden, Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III

10.1136/ijgc-2021-ESGO.511

Introduction/Background* Dickkopf-1 (DKK-1) is a secreted protein, known for suppressing the differentiation and activity of bone-building osteoblasts by acting as an inhibitor of Wnt-signalling. Soluble DKK-1 (sDKK-1) has been proposed as prognostic biomarker for a wide range of malignancies, however, clinical relevance of sDKK-1 as potential blood-based marker for ovarian cancer is unknown.

Methodology sDKK-1 levels were quantified in a cohort of 150 clinically documented ovarian cancer patients by a commercially available DKK-1 ELISA (Biomedica, Vienna, Austria). **Result(s)*** Median sDKK-1 level was significantly elevated at primary diagnosis of ovarian cancer compared to healthy controls (estimated difference (ED) of 7.75 ng/mL (95%CI: 3.01 – 12.30 ng/mL, $p = 0.001$). Higher levels of sDKK-1 at diagnosis indicated an increased volume of intraoperative malignant ascites (ED 7.08 pmol/L, 95%CI: 1.46 – 13.05, $p = 0.02$) and predicted suboptimal debulking surgery (ED 6.88 pmol/L, 95%CI: 1.73 – 11.87, $p = 0.01$). sDKK-1 did not correlate with CA125, and higher sDKK-1 levels predicted a higher risk of recurrence and poor survival (PFS: HR = 0.507, 95%CI: 0.317 – 0.809; $p = 0.004$; OS: HR = 0.561, 95%CI: 0.320 – 0.986; $p = 0.044$). Prognostic relevance of sDKK-1 was partly sustained in wtBRCA patients (PFS: HR = 0.507, 95%CI: 0.317 – 0.809; $p = 0.004$).

Conclusion* This is the first study demonstrating the prognostic relevance of sDKK-1 in ovarian cancer patients, including those with wtBRCA1/2 status. Our data encourage further evaluation of sDKK-1 in ovarian cancer patients, possibly in terms of a therapy monitoring marker or a response predictor for sDKK-1-directed targeted therapies.

1064

ROLE OF CA 125, HE4 AND IOTA SIMPLE RULES IN DIFFERENTIATING BENIGN AND MALIGNANT OVARIAN TUMOUR

A Bahadur, R Mundhra*, N Bhattacharya. *aiims rishikesh, obs gynae, rishikesh, India*

10.1136/ijgc-2021-ESGO.512

Introduction/Background* This study aimed to evaluate the diagnostic added-value of serum CA-125 & HE4 to the International Ovarian Tumor Analysis (IOTA) Simple Rules for differentiating malignant and benign ovarian tumors preoperatively.

Methodology A Cross sectional study was conducted in the Department of Obstetrics and Gynecology on 100 patients with ovarian masses. Demographic and clinical data were prospectively collected. Histopathologic diagnosis was used as the gold standard test. Evaluation of the utility of HE4, CA125 and IOTs simple rules for preoperative identification of malignancy was based on the increment of the area under the receiver operating characteristic curve (AuROC).

Result(s)* Out of the 50 suspected benign masses as per IOTA simple rules, post surgery (considering histopathology as gold standard) 32 (64%) were diagnosed as benign ovarian masses, 4 (8%) borderline and 14 (28%) other malignant ovarian tumors on final histopathology. Out of 50 suspected malignant masses as per IOTA simple rules, 26 (52%) were finally diagnosed as benign, 4(8%) borderline and 20 (40%) were malignant. Sensitivity of combined testing of both tumour markers (HE4 and Ca-125) and IOTA together was calculated to be a 85.3% (69-95) whereas its specificity increased to be 94.8% (86-99). Positive predictive value was determined to 90.6% (75-98) and negative predictive value was calculated 91.7% (82-97) making its diagnostic accuracy as 91.3% (84-96).

Conclusion* Combining IOTA Simple rules with known tumour markers (CA125 and HE4) increases diagnostic accuracy in predicting malignant ovarian masses preoperatively

1068

BRCA GERMLINE MUTATION FREQUENCY AND THE EFFECTS ON ONCOLOGIC OUTCOMES AMONG NORWEGIAN OVARIAN CANCER PATIENTS

¹A Birgisdottir*, ²M Bjørnslett, ³S Aaserud, ¹T Paulsen, ¹A Dørum. ¹The Norwegian Radium Hospital, Department of Gynecological Oncology, Oslo, Norway; ²Oslo University Hospital, Department of Molecular Oncology, Oslo, Norway; ³The Norwegian Cancer Registry, Oslo

10.1136/ijgc-2021-ESGO.513

Introduction/Background* Germline mutations in the BRCA1 and BRCA2 genes (BRCAg) are a known risk factor for development of breast and epithelial ovarian cancer (OC). We describe the frequency of BRCAg carriers, the clinical features and survival in Norwegian OC patients.

Methodology This is a prospective cohort study including OC patients at the Norwegian Radium Hospital (covering 50% of the Norwegian population) from Jan 1st 2014 to Dec 31st 2019. Included are the patients which accepted BRCAg test after giving informed consent. DNA was isolated from peripheral blood, and mutation analyses performed with Sanger sequencing and multiplex ligation probe amplification. Data on family history, BRCAg test results was registered and data on clinical features and histopathology was collected from the department's quality database. All statistical analyses were performed using the Stata (Stata/MP 17.1) program, Chi-square

Abstract 1068 Figure 1 Kaplan-Meier survival analysis

test for independence of groups and Kaplan-Meier survival analysis.

Result(s)* Altogether 73% of OC patients accepted *BRCAG* test and were included in the study ($n=1049$), 83 (7.9%) had a *BRCAG*, of which 46 (4.4%) had mutation in *BRCA1* and 37 (3.5%) in *BRCA2*. Assuming that the *BRCAG* frequency is not higher among the not tested compared to the tested and lowest 0, we estimate 5.7-7.9% *BRCAG* frequency in our OC population.

The patients with *BRCAG* were younger at diagnosis (mean age 59.9 y vs. 63.3 y $p=0.005$), had more often high-grade serous histology (95% vs. 67% $p<0.0001$), had more advanced disease (FIGO stage III-IV) at the time of diagnosis (83% vs. 71% $p=0.003$) and more often received neoadjuvant chemotherapy (28% vs. 15% $p=0.04$) compared to non-mutation carriers. Patients with FIGO stage III-IV and *BRCAG* had a better overall survival compared to non-mutation carriers (median OS 76.4 months vs. 42.1 months $p=0.03$, figure 1). However, the difference in progression free survival between the two groups was non-significant (median PFS 31.1 months vs. 30.3 months $p=0.87$).

Conclusion* In our study population the *BRCAG* frequency was 7, 9% and *BRCAG* was found to be a significant prognostic factor.

1086

ABSTRACT WITHDRAWN

1094

MIRRORS STUDY: A PROSPECTIVE COHORT STUDY ASSESSING THE FEASIBILITY OF ROBOTIC INTERVAL DEBULKING SURGERY FOR ADVANCED-STAGE OVARIAN CANCER

¹C Uwins*, ¹J Read, ¹A Tailor, ¹J Chatterjee, ¹P Ellis, ²S Skene, ³A Michael, ¹S Butler-Manuel. ¹Royal Surrey NHS Foundation Trust, Academic Department of Gynaecological Oncology, Guildford, UK; ²University of Surrey, Surrey Clinical Trials Unit, Guildford, UK; ³University Of Surrey, School of Biosciences and Medicine, UK

10.1136/ijgc-2021-ESGO.514

Introduction/Background* MIRRORS (*Minimally Invasive Robotic surgery, Role in optimal debulking Ovarian cancer, Recovery & Survival*) is the largest prospective cohort study of robotic interval debulking surgery (IDS) in women with advanced-stage epithelial ovarian cancer (EOC) to date. MIRRORS has investigated the feasibility of obtaining consent

from women, the acceptability and success of robotic IDS and its impact on short-term surgical outcomes and quality of life.

Methodology

Eligibility Women with FIGO IIIc-IVb EOC undergoing neoadjuvant chemotherapy and suitable for IDS. Exclusions: pelvic mass >8cm, extensive HPB and/or extensive bowel involvement.

Surgery commenced with an initial laparoscopic assessment, for all women recruited, followed by a decision to proceed immediately to robotic or open IDS.

Result(s)* 23/24 eligible women recruited. Following initial diagnostic laparoscopy, 20 women proceeded directly to robotic IDS, 3 women received open IDS. All patients were debulked with maximal surgical effort to $R<1$, 39% to $R=0$. No robotic cases were converted to open. Median EBL for robotic IDS: 50ml, open: 2026ml, median operating time 05:58 robotic vs 05:38 open, length of stay (LOS) 1.5 days robotic vs 6 days open. Bowel resection with stapled anastomosis 15% (3/20), diaphragmatic stripping 60% (12/20), full-thickness diaphragmatic resection 5% (1/20), pelvic peritoneal stripping 70% (14/20).

Conclusion* MIRRORS has shown significantly enhanced recovery with short LOS, reduced blood loss and reduced HDU/ITU demands, enabling faster re-commencement of chemotherapy in women with FIGO IIIc-IVb EOC. This proved to be greatly beneficial during the COVID-19 pandemic. In

Abstract 1094 Figure 1

Abstract 1094 Figure 2